ライフサイエンスコーパス: salbutamol

1 fter the use of a bronchodilator (400 mug of salbutamol).

2 on of a shortacting beta(2) agonist (180 mug salbutamol).

3 nse to an endothelium-dependent vasodilator (salbutamol).

4 ation can be measured by FMD and by PWA with salbutamol.

5 em shows an intrinsic efficacy comparable to salbutamol.

6 turally related non-catechol partial agonist salbutamol.

7 ss (p<0.001), in the group receiving regular salbutamol.

8 The change in VMAX was partially blocked by salbutamol.

9 These changes were blocked by salbutamol.

10 chronic stimulation was partially blocked by salbutamol.

11 peated following administration of nebulized salbutamol.

12 the beta2 adrenergic agonist (beta2-agonist) salbutamol.

13 or combined with 3,4-diaminopyridine and/or salbutamol.

14 on to ICS and the short-acting beta2-agonist salbutamol.

15 ng treatment with salmeterol, formoterol, or salbutamol.

16 mine and norepinephrine but not with that of salbutamol.

17 CT00494624) used high-dose regular nebulized salbutamol (0.15 mg/kg 2-4 h intervals) and Vinku2 used

18 by 59 +/- 7% (n = 5) and inhibited those to salbutamol (0.3 to 3.5 nmol.min-1) by 52 +/- 6% (n = 8).

19 Cumulative doses of salbutamol (0.3 to 3.5 nmol.min-1) did not cause tachyph

20 Salbutamol (1-10 microM) inhibited iKCa1 currents follow

21 AR stimulation with epinephrine 10(-6) M and salbutamol 10(-6)-10(-5) M yielded a strong cyclic adeno

22 rmoterol 3 mug, two actuations as needed, or salbutamol 100 mug, two actuations as needed.

23 ombination MDI with one to two actuations of salbutamol (100 mug per actuation) by MDI as needed for

24 (69-201 ppb) and to control eyes spiked with salbutamol (100 ppb) and terbutaline (25-100 ppb).

25 ere randomized to treatment with intravenous salbutamol (15 microg kg(-1) h(-1)) or placebo for 7 d.

26 set were randomly assigned to receive either salbutamol (15 mug/kg ideal bodyweight per h) or placebo

27 65 of 69 patients who received ephedrine or salbutamol, 18 of 29 who were given 3,4-diaminopyridine,

28 Salbutamol (2.5 mg) was administered by inhalation.

29 e samples (91) from athletes with detectable salbutamol (30) and negative samples (61) were analyzed

30 ctivation of beta2 adrenergic receptors with salbutamol (40 microm) or formoterol (5 microm) resulted

31 was no evidence that regular use of inhaled salbutamol 400 microg four times daily for a year increa

32 efore inhalation of a bronchodilating agent (salbutamol 400 mug), and one set was acquired after.

33 HI reversibility after administration of salbutamol (400 mug) was defined as a decrease in RV >20

34 Salbutamol, a beta 2-agonist, increased the weight of th

35 (iv) Salbutamol, a beta-AR partial agonist, acutely decreased

36 of the NMJ were used to study the effect of salbutamol, a beta2-adrenergic agonist, on synaptic stru

37 in 4 million Norwegians, the beta2AR agonist salbutamol, a brain-penetrant asthma medication, was ass

38 nd engage the rotamer toggle switch, whereas salbutamol, a noncatechol partial agonist only breaks th

39 agonist, norepinephrine; a partial agonist, salbutamol; a weak partial agonist, dopamine; a very wea

40 = 1.5) or 'extreme' salbutamol overuse (> 32 salbutamol actuations/24-h period).

41 and purine metabolism have association with salbutamol administration.

42 Similarly, the beta2 agonist salbutamol also could induce Ca(2+) shuttling from cytop

43 Formoterol and salbutamol also showed anti-inflammatory properties.

44 osure to beta2-adrenoceptor agonists such as salbutamol, an effect postulated to operate via intracel

45 We further demonstrate that bronchodilators salbutamol and adrenaline effectively reversed these obs

46 sed by administering bronchodilators such as salbutamol and adrenaline.

47 ol and isoprenaline and the partial agonists salbutamol and dobutamine.

48 The use of salbutamol and ephedrine alone or combined with pyridost

49 The beta-adrenergic agonists salbutamol and ephedrine have proven to be effective as

50 ntake of small amounts of the model compound salbutamol and explore a sensitive approach to help scre

51 andomly allocated (1:1) to receive nebulised salbutamol and ipratropium bromide with either 2.5 mL of

52 essment, including responsiveness to inhaled salbutamol and ipratropium bromide.

53 that the release was partially inhibited by salbutamol and salmeterol.

54 Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazod

55 a short-acting beta(2)-adrenoceptor agonist (salbutamol) and a short-acting anticholinergic (ipratrop

56 Albuterol (salbutamol) and glyceryl trinitrate (GTN) were administe

57 cAMP production in response to short-acting (salbutamol) and long-acting (formoterol) beta2 -agonists

58 ilator (ie, before administration of 200 mug salbutamol) and post-bronchodilator (ie, after administr

59 ollen sensitization, FEV(1)% predicted after salbutamol, and annual asthma exacerbation frequency dur

60 Our results using atenolol, salbutamol, and cocaine as test compounds show that we c

61 most beta2-AR agonists, including zinterol, salbutamol, and procaterol, was potentiated by PTX, indi

62 ngly, the beta-adrenergic receptor agonists, salbutamol, arterenol and isoproterenol were also able t

63 stemic corticosteroid for 3 days and inhaled salbutamol as long as they needed.

64 mation for clinicians considering metrics of salbutamol as predictors of future adverse outcomes in a

65 gimen (SMART) with a fixed-dose regimen with salbutamol as reliever ('Standard'), actual medication u

66 pranolol (non-selective beta-antagonist) and salbutamol (beta(2)-agonist), which are known to alter t

67 1; mean +/- SD) but only weak relaxations to salbutamol (beta(2)-receptor agonist; 13 +/- 3%; P < 0.0

68 pproaches, we show that the aromatic ring of salbutamol binds to a different site on the beta(2)AR th

69 Simultaneous administration of salbutamol blocked these changes in protein expression a

70 Anti-TNF and salbutamol both suppressed clinical arthritis more effec

71 easurements of vascular responses to inhaled salbutamol by pulse wave analysis (PWA) or pulse contour

72 The data demonstrate that salbutamol can prolong survival and increase NMJ number

73 fate to SABA, and levosalbutamol compared to salbutamol cannot be recommended in routine practice.

74 It is of particular interest that salbutamol changed the relative levels of SERCA proteins

75 In this study, we show that salbutamol closes iKCa1 in mast cells derived from human

76 The drugs salmeterol, formoterol, and salbutamol constitute the frontline treatment of asthma

77 Combination therapy with pyridostigmine and salbutamol counteracted this decline (P < 0.001).

78 Salbutamol decreased the levels of the slow-twitch cardi

79 Salbutamol did not change the level of myosin heavy chai

80 Salbutamol did not produce these effects in the vastus i

81 periments indicate that the aromatic ring of salbutamol does not activate this mechanism either direc

82 utamol pMDIs with HFA-152a and HFA-134a, and salbutamol dry-powder inhaler (DPI).

83 Treatment with intravenous salbutamol early in the course of ARDS was poorly tolera

84 Salmeterol and salbutamol enhanced rhinovirus- and IL-1beta-induced IL-

85 The salbutamol enhanced the electrochemiluminescence signal

86 Salbutamol enhances neuromuscular junction synaptic stru

87 ular coherence and tremor, and the fact that salbutamol enhances tremor but does not affect coherence

88 Intravenous salbutamol failed to reduce Rp as effectively in challen

89 ple and sensitive electrochemical sensing of salbutamol for controlling the health of food.

90 rmoterol reliever monotherapy is superior to salbutamol for preventing asthma attacks, with a similar

91 olled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in patients with acute respi

92 nity or selectivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adren

93 wer Murray lung injury score at Day 7 in the salbutamol group (1.7 +/- 0.9) versus placebo (2.0 +/- 0

94 au airway pressure was lower at Day 7 in the salbutamol group (23.9 +/- 3.8 cm H2O) versus placebo (2

95 sonide-formoterol group and 167 (92%) in the salbutamol group (odds ratio 0.79 [95% CI 0.35-1.79]).

96 We randomly assigned 162 patients to the salbutamol group and 164 to the placebo group.

97 Patients in the salbutamol group had a higher incidence of supraventricu

98 Patients in the salbutamol group had significantly lower lung water at D

99 tality (55 [34%] of 161 patients died in the salbutamol group vs 38 (23%) of 163 in the placebo group

100 sonide-formoterol group and 181 [50%] to the salbutamol group).

101 the budesonide-formoterol group than in the salbutamol group-cluster-adjusted rates 0.23 versus 0.41

102 An enantioselective synthesis of (R)-salbutamol has been carried out using the chiral, C2 sym

103 Treatment groups included salbutamol high-dose vs. salbutamol on-demand while adju

104 In the duration of hospitalization, salbutamol high-dose/placebo versus salbutamol on-demand

105 thin 30 min) after treatment with 400 mug of salbutamol in a metered-dose inhaler with or without a s

106 ep towards ensuring future patient access to salbutamol in a pMDI.

107 nfirm the efficacy and safety of intravenous salbutamol in ALI/ARDS, this trial provides the first pr

108 nsor is well suited for the determination of salbutamol in milk, sausage, and livestock and poultry f

109 s established for the rapid determination of salbutamol in pork samples.

110 group or more than 16 actuations per day of salbutamol in the standard group).

111 Salbutamol increased 28-day mortality (55 [34%] of 161 p

112 The uphill step in the partial agonist salbutamol induced activation is distinct from full agon

113 in neutrophils from healthy volunteers with salbutamol-induced dysfunction and extended to demonstra

114 -9.68 +/- 0.07, n = 17, for isoprenaline and salbutamol-induced responses, respectively).

115 ed in 68 asthmatic patients before and after salbutamol inhalation.

116 ly and group B (40 patients) received rescue salbutamol inhalation.

117 Mean total carbon footprint per salbutamol inhaler (based on 100-year global warming pot

118 2%]; adjusted HR, 1.22 [95% CI, 1.11-1.34]), salbutamol inhaler prescription at age 5 years (10.34% v

119 risk of asthma requiring hospital admission, salbutamol inhaler prescription at age 5 years, and all-

120 hospital admission; secondary outcomes were salbutamol inhaler prescription at age 5 years, obesity

121 risk of asthma requiring hospital admission, salbutamol inhaler prescription at age 5 years, obesity

122 ydrofluoroalkane (HFA)-152a, against current salbutamol inhalers.

123 ColQ-/- mice received 7 weeks of daily salbutamol injection, and the effect on muscle strength

124 A third group (30) was created by spiking salbutamol into negative samples to eliminate confoundin

125 Oral salbutamol is a symptomatic treatment option in survivor

126 3, TM5, and TM6, whereas the binding site of salbutamol is shifted toward TM4.

127 This analysis suggests that (1) ephedrine or salbutamol is the first choice of treatment in DOK7 CMS;

128 Salbutamol is used as a prohibited additive in animal an

129 We show that salbutamol leads to a gradual improvement in muscle stre

130 of agonist norepinephrine or partial agonist salbutamol leads to the selection of a subset of conform

131 Instead, we suggest that propranolol and salbutamol may affect both tremor and corticomuscular co

132 inovirus-induced wheezing, high-dose inhaled salbutamol may interact with oral prednisolone.

133 e beta2 adrenoceptor agonists formoterol and salbutamol mediated suppression of IL-27p28 production,

134 opionate and beta(2) agonists salmeterol and salbutamol on IL-6 production in BEAS-2B and primary bro

135 pplication of chronic muscle stimulation and salbutamol on the expression of mRNAs and proteins norma

136 ent groups included salbutamol high-dose vs. salbutamol on-demand while adjusting for prednisolone st

137 /kg 2-4 h intervals) and Vinku2 used inhaled salbutamol on-demand.

138 ization, salbutamol high-dose/placebo versus salbutamol on-demand/placebo groups did not differ (p =

139 opener 1-EBIO, and was reversed by removing salbutamol or by the addition of the selective beta2-adr

140 tients were randomised to receive 400 microg salbutamol or matched placebo via a Diskhaler four times

141 nce of isoprenaline and adrenaline than when salbutamol or terbutaline were present (e.g., log KD pro

142 antiinterleukin-12 (anti-IL-12) antibodies, salbutamol, or indomethacin.

143 riation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infa

144 in 1 h) alongside standard therapy including salbutamol, or placebo control plus standard therapy alo

145 asthma control (ACQ-5 >/= 1.5) or 'extreme' salbutamol overuse (> 32 salbutamol actuations/24-h peri

146 ted with an increased risk of future extreme salbutamol overuse.

147 re identified as hypoxanthine increased with salbutamol (p < 0.001).

148 w-mediated dilation (p < 0.001) and PWA with salbutamol (p = 0.03) responses fell after typhoid vacci

149 o select features correlated with detectable salbutamol (p(corr) > 0.5) and ROC analysis was performe

150 si muscle and simultaneous administration of salbutamol partially blocked this change.

151 2 signaling complex, beta(2)-AR stimulation (salbutamol plus atenolol) of I(Ca,L) was examined in per

152 This study compared GHG emissions of a salbutamol pMDI using a low-carbon propellant in clinica

153 e > 90% reduction in the carbon footprint of salbutamol pMDI versus the currently used HFA-134a.

154 The development of salbutamol pMDI with HFA-152a is a crucial step towards

155 lifecycle analyses compared GHG emissions of salbutamol pMDIs with HFA-152a and HFA-134a, and salbuta

156 a dynamic harmonic regression (DHR) model to salbutamol prescribing in relation to temperature.

157 Salbutamol prescriptions ranged from 5% (22 of 432) in t

158 eral well-known beta2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol).

159 Correlation with salbutamol (r = 0.415, p < 0.01, Spearman's correlation)

160 Furthermore, salbutamol recovery post-challenge was significantly blu

161 uccessfully applied for the determination of salbutamol residuals in pork samples.

162 Salbutamol responses were more variable with PWA (adults

163 tion, treatment with 3,4-diaminopyridine and salbutamol resulted in motor and respiratory function im

164 e (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were dis

165 nitude of treatment effect with ephedrine or salbutamol seems to increase gradually, peaking after ap

166 Whilst salbutamol significantly increased tremor amplitude as e

167 dilator (ie, after administration of 200 mug salbutamol) small airways obstruction for each site.

168 Virtual ligand screening with the salbutamol-stabilized conformation shows enrichment of n

169 stamine infusions, volume resuscitation, and salbutamol sulfate inhalation, which resulted in an impr

170 imulations with the G protein-biased agonist salbutamol that involves perturbations of the network of

171 We observed a novel secondary path for salbutamol that is distinct from its primary route.

172 study the effects of regular use of inhaled salbutamol, the most widely prescribed bronchodilator in

173 le would have to be treated for 5 years with salbutamol to prevent Parkinson's disease in one patient

174 the addition of the beta2-adrenergic agonist salbutamol to the anticholinesterase medication pyridost

175 the improvement seen in patients from adding salbutamol to their medication can be explained in an ex

176 0.30 mug/min and 0.60 mug/min intracoronary salbutamol) to measure changes in segmental lumen volume

177 In addition, the neuromuscular junctions of salbutamol treated mice showed significant improvements

178 observed in homogenates of muscles from the salbutamol-treated animals and could partially account f

179 cted by fluorescent labelling, but following salbutamol treatment an increased number were detectable

180 Salbutamol treatment improved weight gain and survival i

181 Salbutamol treatment increased the number of detectable

182 Here, we investigated the effect of salbutamol treatment on the neuromuscular junction in th

183 The aim of TRUST (The Regular Use of Salbutamol Trial) was to study the effects of regular us

184 eported (day- and nighttime asthma symptoms, salbutamol usage, and 7-item-Asthma Control Questionnair

185 ) (95% CI) 1.24 (1.06-1.46)], higher days of salbutamol use (per 2 days in 2 weeks) [OR 1.15 (1.00-1.

186 Higher mean daily salbutamol use (per two actuations/day) [Odds ratio (OR)

187 Higher mean daily salbutamol use [OR 2.73 (1.84-4.07)], number of days of

188 e relationships between different metrics of salbutamol use and future risk are uncertain.

189 Electronically recorded frequency of current salbutamol use is a strong predictor of risk of future a

190 the relationship between metrics of baseline salbutamol use over 2 weeks and future severe asthma exa

191 Higher mean daily salbutamol use was associated with future poor asthma co

192 asthma control, exacerbations, and increased salbutamol use.

193 with chronic beta-adrenoceptor agonist (eg, salbutamol) use, and by functional data indicating a pos

194 Oral salbutamol used empirically in 16/37 (43.2%) offspring r

195 B2-AR agonists, salmeterol, formoterol, and salbutamol, using advanced simulation techniques.

196 Bronchodilation after salbutamol was equal to or greater than that after iprat

197 Salbutamol was more than 100 times as potent as dobutami

198 n of salmeterol and formoterol compared with salbutamol were attributed, at least in part, to their h

199 Odds of exposure to salbutamol were similar.